Orthocell (ASX:OCC) finalized an agreement with Marine Biomedical, increasing its equity interest to 11.7% from 1.72% for a total investment of AU$1.1 million, according to a Friday filing with the Australian bourse.
The company also secured global distribution rights to PearlBone, Marine Biomedical's bone regeneration technology, as well as its future bone repair products under the deal, the filing said.